Nektar to cut over 500 jobs following cancer drug failure
(Reuters) – Nektar Therapeutics said on Monday it would lay off about 70% of its workforce, or more than 500 employees, after stopping the development of its key cancer drug…
(Reuters) – Nektar Therapeutics said on Monday it would lay off about 70% of its workforce, or more than 500 employees, after stopping the development of its key cancer drug…
(Reuters) – Nektar Therapeutics said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer’s shares down 23% in…